New drug shows promise for fatty liver disease in early trial

NCT ID NCT06104319

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a single dose of the experimental drug GSK4532990 in 61 adults with NASH, a type of fatty liver disease. Researchers measured how the drug moves through the body and affects liver proteins, while also checking for safety. The goal is to see if the drug can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK4532990
What this could lead to: If successful, this could point toward a treatment for non-alcoholic steatohepatitis (NASH), a serious liver disease.
What could go wrong: This is an early-phase study with only 61 participants, so results may not confirm effectiveness or safety for wider use. The drug may not improve liver health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

GSK Investigational Site

Chula Vista, California, 91911, United States
GSK Investigational Site

Montclair, California, 91763, United States
GSK Investigational Site

San Diego, California, 91911, United States
GSK Investigational Site

San Diego, California, 91942, United States
GSK Investigational Site

Brandon, Florida, 33511, United States
GSK Investigational Site

Miami, Florida, 33155, United States
GSK Investigational Site

Miami, Florida, 33173, United States
GSK Investigational Site

Miami Lakes, Florida, 33014, United States
GSK Investigational Site

Indianapolis, Indiana, 46202, United States
GSK Investigational Site

El Dorado, Kansas, 67042, United States
GSK Investigational Site

Marrero, Louisiana, 70072, United States
GSK Investigational Site

Austin, Texas, 78745, United States
GSK Investigational Site

San Antonio, Texas, 78215, United States
GSK Investigational Site

San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.